Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 238 | 2024 | 6211 | 21.670 |
Why?
|
Allergens | 88 | 2024 | 1410 | 11.960 |
Why?
|
Air Pollution, Indoor | 51 | 2024 | 899 | 10.610 |
Why?
|
Schools | 51 | 2024 | 1488 | 8.450 |
Why?
|
Environmental Exposure | 80 | 2024 | 4467 | 7.900 |
Why?
|
Hypersensitivity | 36 | 2024 | 1158 | 7.250 |
Why?
|
Anti-Asthmatic Agents | 32 | 2024 | 573 | 5.870 |
Why?
|
Food Hypersensitivity | 24 | 2024 | 708 | 5.450 |
Why?
|
Urban Population | 36 | 2024 | 2036 | 5.340 |
Why?
|
Bronchodilator Agents | 17 | 2022 | 512 | 3.370 |
Why?
|
Cockroaches | 16 | 2022 | 97 | 3.070 |
Why?
|
Adrenal Cortex Hormones | 35 | 2024 | 1876 | 2.930 |
Why?
|
Dust | 16 | 2024 | 487 | 2.650 |
Why?
|
Child | 201 | 2024 | 80162 | 2.590 |
Why?
|
Skin Tests | 19 | 2020 | 637 | 2.580 |
Why?
|
Immunoglobulin E | 27 | 2023 | 1495 | 2.490 |
Why?
|
Eczema | 7 | 2024 | 245 | 2.480 |
Why?
|
Egg Hypersensitivity | 5 | 2020 | 47 | 2.340 |
Why?
|
Dermatitis, Atopic | 11 | 2024 | 721 | 2.240 |
Why?
|
Fungi | 13 | 2023 | 338 | 2.150 |
Why?
|
Housing | 14 | 2023 | 670 | 1.920 |
Why?
|
Pest Control | 4 | 2019 | 29 | 1.750 |
Why?
|
School Health Services | 8 | 2024 | 384 | 1.580 |
Why?
|
Endotoxins | 5 | 2018 | 521 | 1.580 |
Why?
|
Spirometry | 12 | 2024 | 928 | 1.520 |
Why?
|
Desensitization, Immunologic | 9 | 2024 | 545 | 1.510 |
Why?
|
Biological Products | 7 | 2023 | 912 | 1.470 |
Why?
|
Hypersensitivity, Immediate | 9 | 2024 | 345 | 1.430 |
Why?
|
Child, Preschool | 79 | 2024 | 42254 | 1.400 |
Why?
|
Milk Hypersensitivity | 3 | 2020 | 78 | 1.360 |
Why?
|
Air Pollutants | 17 | 2024 | 2881 | 1.340 |
Why?
|
Nitrogen Dioxide | 5 | 2024 | 520 | 1.300 |
Why?
|
Humans | 325 | 2024 | 761423 | 1.280 |
Why?
|
Ibuprofen | 3 | 2021 | 229 | 1.280 |
Why?
|
Pyroglyphidae | 7 | 2018 | 88 | 1.240 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 4 | 2019 | 111 | 1.230 |
Why?
|
Air Pollution | 9 | 2024 | 2348 | 1.180 |
Why?
|
Respiratory Sounds | 8 | 2021 | 701 | 1.150 |
Why?
|
Administration, Inhalation | 25 | 2024 | 1156 | 1.140 |
Why?
|
Urban Health | 6 | 2019 | 533 | 1.110 |
Why?
|
Cats | 12 | 2018 | 975 | 1.100 |
Why?
|
Viruses | 2 | 2021 | 376 | 1.090 |
Why?
|
Forced Expiratory Volume | 20 | 2024 | 1812 | 1.070 |
Why?
|
Psychology | 2 | 2019 | 356 | 1.060 |
Why?
|
Respiratory Function Tests | 16 | 2024 | 1682 | 1.010 |
Why?
|
Morbidity | 15 | 2023 | 1750 | 0.970 |
Why?
|
Adolescent | 91 | 2024 | 88313 | 0.960 |
Why?
|
Ovomucin | 2 | 2013 | 7 | 0.900 |
Why?
|
Snoring | 2 | 2024 | 209 | 0.870 |
Why?
|
Antigens, Dermatophagoides | 7 | 2021 | 97 | 0.850 |
Why?
|
Caregivers | 9 | 2024 | 2237 | 0.850 |
Why?
|
Air Microbiology | 3 | 2019 | 95 | 0.840 |
Why?
|
Anaphylaxis | 5 | 2019 | 757 | 0.800 |
Why?
|
Phthalic Acids | 2 | 2024 | 478 | 0.790 |
Why?
|
Rodent Control | 1 | 2021 | 15 | 0.780 |
Why?
|
Mice | 38 | 2024 | 81509 | 0.780 |
Why?
|
Dogs | 11 | 2022 | 3839 | 0.780 |
Why?
|
Rodenticides | 2 | 2021 | 21 | 0.770 |
Why?
|
Male | 139 | 2024 | 360736 | 0.770 |
Why?
|
Eggs | 2 | 2013 | 182 | 0.770 |
Why?
|
Medication Adherence | 9 | 2024 | 2176 | 0.750 |
Why?
|
Spores, Fungal | 2 | 2019 | 90 | 0.750 |
Why?
|
Female | 142 | 2024 | 392581 | 0.730 |
Why?
|
Eosinophils | 10 | 2024 | 948 | 0.730 |
Why?
|
Nut Hypersensitivity | 2 | 2010 | 32 | 0.730 |
Why?
|
Pregnenediones | 4 | 2022 | 29 | 0.710 |
Why?
|
Leukotriene Antagonists | 4 | 2016 | 124 | 0.710 |
Why?
|
Rodentia | 3 | 2019 | 262 | 0.710 |
Why?
|
Cities | 6 | 2024 | 546 | 0.700 |
Why?
|
Ozone | 1 | 2023 | 482 | 0.690 |
Why?
|
Virus Diseases | 2 | 2017 | 719 | 0.680 |
Why?
|
Animals | 75 | 2024 | 168441 | 0.680 |
Why?
|
Acetaminophen | 4 | 2021 | 554 | 0.680 |
Why?
|
Nitric Oxide | 7 | 2023 | 2133 | 0.660 |
Why?
|
Rhinovirus | 5 | 2023 | 202 | 0.660 |
Why?
|
Alternaria | 1 | 2019 | 42 | 0.650 |
Why?
|
Anti-Allergic Agents | 2 | 2020 | 150 | 0.640 |
Why?
|
Climate Change | 3 | 2017 | 496 | 0.640 |
Why?
|
Vehicle Emissions | 2 | 2024 | 655 | 0.640 |
Why?
|
Epinephrine | 3 | 2017 | 792 | 0.630 |
Why?
|
Mentors | 1 | 2024 | 660 | 0.620 |
Why?
|
Antibodies, Blocking | 1 | 2019 | 243 | 0.620 |
Why?
|
Acute Chest Syndrome | 1 | 2018 | 32 | 0.620 |
Why?
|
Hospitals, Pediatric | 2 | 2018 | 1862 | 0.610 |
Why?
|
Insect Bites and Stings | 2 | 2017 | 71 | 0.600 |
Why?
|
Albuterol | 5 | 2019 | 213 | 0.600 |
Why?
|
Respiratory Tract Diseases | 2 | 2013 | 748 | 0.580 |
Why?
|
Exhalation | 2 | 2016 | 181 | 0.580 |
Why?
|
Oxidants, Photochemical | 1 | 2017 | 76 | 0.570 |
Why?
|
Inhalation Exposure | 1 | 2020 | 431 | 0.570 |
Why?
|
Students | 9 | 2023 | 1741 | 0.570 |
Why?
|
Policy | 2 | 2019 | 508 | 0.550 |
Why?
|
Maximal Midexpiratory Flow Rate | 2 | 2016 | 76 | 0.550 |
Why?
|
Double-Blind Method | 22 | 2024 | 12330 | 0.540 |
Why?
|
Antibodies, Anti-Idiotypic | 2 | 2015 | 357 | 0.540 |
Why?
|
Jews | 1 | 2018 | 364 | 0.530 |
Why?
|
Obesity | 10 | 2023 | 12938 | 0.530 |
Why?
|
Plant Proteins | 2 | 2021 | 369 | 0.520 |
Why?
|
Severity of Illness Index | 25 | 2024 | 15838 | 0.520 |
Why?
|
Interleukin-4 Receptor alpha Subunit | 4 | 2022 | 57 | 0.510 |
Why?
|
Bronchoconstriction | 1 | 2016 | 142 | 0.510 |
Why?
|
Toxocariasis | 1 | 2015 | 12 | 0.500 |
Why?
|
Infant | 30 | 2024 | 36205 | 0.490 |
Why?
|
Picornaviridae Infections | 3 | 2023 | 94 | 0.490 |
Why?
|
Enterocolitis | 3 | 2021 | 106 | 0.490 |
Why?
|
Particulate Matter | 10 | 2024 | 2595 | 0.470 |
Why?
|
Terbutaline | 1 | 2014 | 23 | 0.470 |
Why?
|
Mycoses | 1 | 2017 | 386 | 0.470 |
Why?
|
Prevalence | 12 | 2024 | 15717 | 0.460 |
Why?
|
United States | 33 | 2024 | 72339 | 0.460 |
Why?
|
Trees | 1 | 2014 | 54 | 0.450 |
Why?
|
Asthma, Exercise-Induced | 1 | 2013 | 23 | 0.450 |
Why?
|
Egg White | 1 | 2013 | 16 | 0.450 |
Why?
|
Peanut Hypersensitivity | 2 | 2021 | 214 | 0.450 |
Why?
|
Milk | 3 | 2020 | 443 | 0.450 |
Why?
|
Immune System | 1 | 2019 | 795 | 0.440 |
Why?
|
Sesamum | 2 | 2010 | 20 | 0.440 |
Why?
|
Rhinitis, Allergic, Seasonal | 1 | 2014 | 105 | 0.430 |
Why?
|
Sputum | 5 | 2024 | 507 | 0.430 |
Why?
|
Nasal Mucosa | 2 | 2019 | 415 | 0.430 |
Why?
|
Environmental Monitoring | 6 | 2024 | 1458 | 0.430 |
Why?
|
Immune Tolerance | 3 | 2020 | 2300 | 0.420 |
Why?
|
Pneumonia | 2 | 2022 | 2140 | 0.420 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2014 | 215 | 0.410 |
Why?
|
Ipratropium | 2 | 2016 | 19 | 0.410 |
Why?
|
Parents | 5 | 2014 | 3564 | 0.410 |
Why?
|
Immunization | 4 | 2010 | 1227 | 0.410 |
Why?
|
Social Class | 4 | 2024 | 2004 | 0.410 |
Why?
|
Acetates | 3 | 2019 | 321 | 0.410 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9179 | 0.410 |
Why?
|
Quality of Life | 14 | 2024 | 13361 | 0.400 |
Why?
|
Genes, Regulator | 1 | 2013 | 374 | 0.400 |
Why?
|
Pesticides | 1 | 2015 | 295 | 0.400 |
Why?
|
Patient Education as Topic | 3 | 2019 | 2319 | 0.390 |
Why?
|
Education | 1 | 2015 | 536 | 0.390 |
Why?
|
Immunity | 1 | 2017 | 997 | 0.390 |
Why?
|
Radon | 2 | 2023 | 87 | 0.390 |
Why?
|
Computer-Assisted Instruction | 1 | 2015 | 362 | 0.380 |
Why?
|
Health Surveys | 2 | 2019 | 4059 | 0.380 |
Why?
|
Pets | 3 | 2019 | 46 | 0.380 |
Why?
|
Prospective Studies | 26 | 2024 | 54415 | 0.380 |
Why?
|
Prolactin | 1 | 2013 | 625 | 0.370 |
Why?
|
Socioeconomic Factors | 6 | 2019 | 7825 | 0.360 |
Why?
|
Cross Reactions | 2 | 2023 | 818 | 0.360 |
Why?
|
Edema | 1 | 2015 | 767 | 0.360 |
Why?
|
Specimen Handling | 1 | 2015 | 702 | 0.360 |
Why?
|
Minority Groups | 8 | 2022 | 1203 | 0.350 |
Why?
|
Bronchiolitis | 1 | 2017 | 485 | 0.350 |
Why?
|
Antibody Specificity | 1 | 2012 | 1060 | 0.350 |
Why?
|
Vital Capacity | 5 | 2024 | 970 | 0.350 |
Why?
|
Risk | 8 | 2020 | 9612 | 0.350 |
Why?
|
School Nursing | 2 | 2022 | 33 | 0.350 |
Why?
|
Cooking | 1 | 2012 | 315 | 0.350 |
Why?
|
Phenols | 2 | 2024 | 517 | 0.350 |
Why?
|
Eosinophilia | 3 | 2023 | 560 | 0.350 |
Why?
|
Monitoring, Physiologic | 2 | 2024 | 1780 | 0.340 |
Why?
|
Bacteria | 2 | 2023 | 2199 | 0.340 |
Why?
|
Rhinitis | 4 | 2014 | 747 | 0.340 |
Why?
|
Safety | 2 | 2014 | 1150 | 0.330 |
Why?
|
Buffaloes | 1 | 2009 | 14 | 0.330 |
Why?
|
Interleukin-6 | 6 | 2023 | 3207 | 0.330 |
Why?
|
Phenotype | 8 | 2020 | 16606 | 0.330 |
Why?
|
Bacterial Infections | 1 | 2017 | 1393 | 0.330 |
Why?
|
Disease Progression | 15 | 2024 | 13502 | 0.330 |
Why?
|
Occupational Diseases | 1 | 2017 | 1490 | 0.330 |
Why?
|
Genes | 1 | 2013 | 1844 | 0.330 |
Why?
|
Residence Characteristics | 2 | 2022 | 2092 | 0.320 |
Why?
|
Epigenesis, Genetic | 3 | 2019 | 3798 | 0.320 |
Why?
|
Bronchopulmonary Dysplasia | 2 | 2024 | 326 | 0.320 |
Why?
|
Quinolines | 3 | 2019 | 764 | 0.310 |
Why?
|
Allergy and Immunology | 3 | 2024 | 176 | 0.310 |
Why?
|
Respiratory Hypersensitivity | 3 | 2016 | 273 | 0.310 |
Why?
|
Glucocorticoids | 6 | 2024 | 2161 | 0.300 |
Why?
|
Cohort Studies | 23 | 2024 | 41446 | 0.300 |
Why?
|
Polymorphism, Genetic | 2 | 2017 | 4287 | 0.290 |
Why?
|
Anti-Infective Agents | 1 | 2015 | 982 | 0.290 |
Why?
|
Adult | 54 | 2024 | 221148 | 0.290 |
Why?
|
Pollen | 3 | 2014 | 81 | 0.280 |
Why?
|
Boston | 8 | 2018 | 9330 | 0.280 |
Why?
|
Vitamins | 3 | 2021 | 1634 | 0.270 |
Why?
|
Breath Tests | 5 | 2023 | 298 | 0.270 |
Why?
|
Treatment Outcome | 21 | 2024 | 64651 | 0.260 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 6132 | 0.250 |
Why?
|
Suburban Population | 1 | 2005 | 53 | 0.250 |
Why?
|
Length of Stay | 2 | 2018 | 6422 | 0.250 |
Why?
|
Enterovirus Infections | 2 | 2023 | 74 | 0.250 |
Why?
|
Environmental Pollutants | 3 | 2024 | 1276 | 0.250 |
Why?
|
Respiratory Insufficiency | 1 | 2014 | 1230 | 0.250 |
Why?
|
Immunotherapy | 3 | 2020 | 4650 | 0.250 |
Why?
|
Risk Factors | 22 | 2024 | 74167 | 0.250 |
Why?
|
Disease Susceptibility | 5 | 2021 | 1793 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2024 | 10203 | 0.240 |
Why?
|
Animals, Domestic | 3 | 2010 | 56 | 0.240 |
Why?
|
Pilot Projects | 7 | 2019 | 8633 | 0.240 |
Why?
|
Peak Expiratory Flow Rate | 3 | 2018 | 144 | 0.240 |
Why?
|
Eosinophil Peroxidase | 1 | 2024 | 21 | 0.240 |
Why?
|
Vitamin D Deficiency | 3 | 2020 | 1386 | 0.240 |
Why?
|
Food | 3 | 2018 | 772 | 0.230 |
Why?
|
Th2 Cells | 3 | 2024 | 1058 | 0.230 |
Why?
|
Conjunctivitis, Allergic | 1 | 2005 | 124 | 0.230 |
Why?
|
Mites | 2 | 2017 | 46 | 0.230 |
Why?
|
Lung | 13 | 2024 | 9995 | 0.230 |
Why?
|
Osteolysis | 1 | 2006 | 275 | 0.220 |
Why?
|
Oscillometry | 1 | 2024 | 150 | 0.220 |
Why?
|
Parabens | 1 | 2024 | 114 | 0.220 |
Why?
|
Solar Activity | 1 | 2023 | 44 | 0.220 |
Why?
|
Poverty | 7 | 2024 | 2697 | 0.220 |
Why?
|
Mass Screening | 2 | 2019 | 5428 | 0.220 |
Why?
|
Azetidines | 1 | 2024 | 140 | 0.220 |
Why?
|
Australia | 2 | 2024 | 1250 | 0.210 |
Why?
|
Research Design | 9 | 2024 | 6178 | 0.210 |
Why?
|
Epithelial Cells | 1 | 2015 | 3667 | 0.210 |
Why?
|
Attitude to Health | 1 | 2012 | 2025 | 0.210 |
Why?
|
Age Factors | 8 | 2024 | 18400 | 0.210 |
Why?
|
Interleukin-4 | 2 | 2024 | 1150 | 0.210 |
Why?
|
Practice Guidelines as Topic | 6 | 2018 | 7389 | 0.210 |
Why?
|
Family Characteristics | 2 | 2024 | 1003 | 0.210 |
Why?
|
Cholecalciferol | 2 | 2020 | 553 | 0.210 |
Why?
|
Churg-Strauss Syndrome | 1 | 2003 | 75 | 0.200 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1669 | 0.200 |
Why?
|
Arthroplasty, Replacement | 1 | 2006 | 310 | 0.200 |
Why?
|
Endogenous Retroviruses | 1 | 2023 | 111 | 0.200 |
Why?
|
DNA Methylation | 3 | 2023 | 4391 | 0.200 |
Why?
|
Ovalbumin | 1 | 2024 | 677 | 0.200 |
Why?
|
Spain | 1 | 2023 | 489 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 2 | 2020 | 1808 | 0.200 |
Why?
|
Stress, Psychological | 1 | 2017 | 4477 | 0.200 |
Why?
|
Pandemics | 7 | 2022 | 8641 | 0.190 |
Why?
|
Inflammation | 10 | 2024 | 10762 | 0.190 |
Why?
|
Environmental Illness | 1 | 2001 | 34 | 0.190 |
Why?
|
Pulmonary Eosinophilia | 1 | 2022 | 78 | 0.190 |
Why?
|
Basophils | 1 | 2024 | 405 | 0.190 |
Why?
|
Muscarinic Antagonists | 1 | 2022 | 135 | 0.190 |
Why?
|
Environment | 2 | 2018 | 1122 | 0.190 |
Why?
|
Cross-Sectional Studies | 9 | 2024 | 26112 | 0.190 |
Why?
|
Pruritus | 2 | 2023 | 380 | 0.190 |
Why?
|
Antiviral Agents | 3 | 2017 | 3057 | 0.180 |
Why?
|
Cysteine Endopeptidases | 2 | 2021 | 551 | 0.180 |
Why?
|
Dyspnea | 4 | 2024 | 1347 | 0.180 |
Why?
|
Cross-Over Studies | 5 | 2019 | 2076 | 0.180 |
Why?
|
Bone Transplantation | 1 | 2006 | 929 | 0.180 |
Why?
|
Epitope Mapping | 1 | 2021 | 297 | 0.180 |
Why?
|
Comorbidity | 6 | 2024 | 10498 | 0.180 |
Why?
|
Young Adult | 19 | 2024 | 59207 | 0.180 |
Why?
|
Genomics | 2 | 2018 | 5820 | 0.180 |
Why?
|
Epitopes | 2 | 2021 | 2507 | 0.180 |
Why?
|
Baltimore | 2 | 2019 | 231 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2015 | 4014 | 0.170 |
Why?
|
Respiratory Tract Infections | 2 | 2020 | 1010 | 0.170 |
Why?
|
Nonlinear Dynamics | 1 | 2022 | 492 | 0.170 |
Why?
|
Mucus | 1 | 2022 | 341 | 0.170 |
Why?
|
Filtration | 2 | 2011 | 228 | 0.170 |
Why?
|
Tosyl Compounds | 1 | 2000 | 115 | 0.170 |
Why?
|
Triamcinolone | 1 | 2019 | 68 | 0.170 |
Why?
|
Health Services | 2 | 2017 | 752 | 0.170 |
Why?
|
Leukocyte Count | 5 | 2024 | 1596 | 0.170 |
Why?
|
Seasons | 3 | 2019 | 1519 | 0.160 |
Why?
|
Nasal Provocation Tests | 1 | 1998 | 9 | 0.160 |
Why?
|
Particle Size | 3 | 2019 | 1646 | 0.160 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 2 | 2019 | 322 | 0.160 |
Why?
|
Sleep Apnea Syndromes | 2 | 2024 | 975 | 0.160 |
Why?
|
Growth Differentiation Factor 15 | 1 | 2020 | 198 | 0.160 |
Why?
|
Infant, Newborn | 7 | 2024 | 26212 | 0.160 |
Why?
|
Extravascular Lung Water | 1 | 2018 | 20 | 0.150 |
Why?
|
Retinal Detachment | 1 | 2023 | 428 | 0.150 |
Why?
|
Dermatophagoides pteronyssinus | 1 | 2018 | 11 | 0.150 |
Why?
|
Blood Gas Monitoring, Transcutaneous | 1 | 2018 | 34 | 0.150 |
Why?
|
Airway Obstruction | 1 | 2023 | 661 | 0.150 |
Why?
|
Azithromycin | 2 | 2019 | 199 | 0.150 |
Why?
|
Larynx | 1 | 2023 | 492 | 0.150 |
Why?
|
Body Mass Index | 6 | 2022 | 12951 | 0.150 |
Why?
|
Health Services Accessibility | 3 | 2024 | 5441 | 0.150 |
Why?
|
History, 21st Century | 1 | 2024 | 1567 | 0.150 |
Why?
|
Antigens, Fungal | 1 | 2017 | 69 | 0.150 |
Why?
|
Maryland | 1 | 2018 | 277 | 0.150 |
Why?
|
National Institute of Environmental Health Sciences (U.S.) | 1 | 2017 | 7 | 0.150 |
Why?
|
Alloys | 1 | 1998 | 110 | 0.150 |
Why?
|
Regional Medical Programs | 1 | 2018 | 66 | 0.150 |
Why?
|
Cost-Benefit Analysis | 2 | 2023 | 5492 | 0.140 |
Why?
|
Venoms | 1 | 2017 | 95 | 0.140 |
Why?
|
Inhalation Spacers | 1 | 2017 | 4 | 0.140 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2017 | 62 | 0.140 |
Why?
|
Symbiosis | 1 | 2019 | 294 | 0.140 |
Why?
|
Glycoproteins | 2 | 2002 | 2208 | 0.140 |
Why?
|
Bedding and Linens | 1 | 2017 | 41 | 0.140 |
Why?
|
Syncope | 1 | 2000 | 427 | 0.140 |
Why?
|
T-Lymphocytes, Regulatory | 3 | 2022 | 3077 | 0.140 |
Why?
|
Polytetrafluoroethylene | 1 | 1998 | 246 | 0.140 |
Why?
|
Population | 1 | 2017 | 141 | 0.140 |
Why?
|
Antibodies, Neutralizing | 3 | 2023 | 1943 | 0.140 |
Why?
|
Body Weights and Measures | 1 | 2017 | 208 | 0.140 |
Why?
|
Th1-Th2 Balance | 1 | 2016 | 38 | 0.140 |
Why?
|
Organizations, Nonprofit | 1 | 2017 | 105 | 0.140 |
Why?
|
Sulfides | 3 | 2019 | 169 | 0.140 |
Why?
|
Bullying | 1 | 2019 | 232 | 0.130 |
Why?
|
Forecasting | 1 | 2005 | 2928 | 0.130 |
Why?
|
Antigens, Plant | 2 | 2021 | 104 | 0.130 |
Why?
|
History, 20th Century | 1 | 2024 | 2769 | 0.130 |
Why?
|
Cyclopropanes | 3 | 2019 | 432 | 0.130 |
Why?
|
Health Status Disparities | 2 | 2020 | 1852 | 0.130 |
Why?
|
Patient Preference | 1 | 2023 | 924 | 0.130 |
Why?
|
Longitudinal Studies | 7 | 2022 | 14599 | 0.130 |
Why?
|
Vitamin D | 4 | 2022 | 3301 | 0.130 |
Why?
|
Middle Aged | 28 | 2024 | 220826 | 0.130 |
Why?
|
Hospitalization | 7 | 2022 | 10718 | 0.130 |
Why?
|
Glutathione | 1 | 2018 | 582 | 0.120 |
Why?
|
Retrospective Studies | 13 | 2023 | 80582 | 0.120 |
Why?
|
Child Day Care Centers | 1 | 2016 | 122 | 0.120 |
Why?
|
Drug Resistance | 2 | 2019 | 1595 | 0.120 |
Why?
|
Sinusitis | 2 | 2013 | 991 | 0.120 |
Why?
|
Sex Factors | 4 | 2018 | 10548 | 0.120 |
Why?
|
Materials Testing | 1 | 1998 | 863 | 0.120 |
Why?
|
Insect Proteins | 1 | 2015 | 254 | 0.120 |
Why?
|
Arginine | 1 | 2018 | 933 | 0.120 |
Why?
|
Standard of Care | 1 | 2018 | 550 | 0.110 |
Why?
|
Clinical Protocols | 3 | 2021 | 1440 | 0.110 |
Why?
|
Insect Control | 1 | 2014 | 29 | 0.110 |
Why?
|
Fluid Therapy | 1 | 2018 | 579 | 0.110 |
Why?
|
Gonadal Steroid Hormones | 1 | 2018 | 702 | 0.110 |
Why?
|
Critical Pathways | 1 | 2017 | 474 | 0.110 |
Why?
|
Nebulizers and Vaporizers | 1 | 2014 | 139 | 0.110 |
Why?
|
Massachusetts | 3 | 2017 | 8832 | 0.110 |
Why?
|
PubMed | 1 | 2014 | 129 | 0.110 |
Why?
|
Dietary Supplements | 3 | 2021 | 3414 | 0.110 |
Why?
|
Antigens, Viral | 1 | 2017 | 988 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2017 | 1571 | 0.110 |
Why?
|
Poverty Areas | 1 | 2015 | 267 | 0.110 |
Why?
|
Drug Therapy, Combination | 4 | 2022 | 6309 | 0.110 |
Why?
|
Colony Count, Microbial | 1 | 2013 | 330 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2023 | 4549 | 0.110 |
Why?
|
Primary Prevention | 2 | 2018 | 1186 | 0.100 |
Why?
|
Administration, Topical | 1 | 2015 | 703 | 0.100 |
Why?
|
Fever | 2 | 2016 | 1618 | 0.100 |
Why?
|
Cyclosporine | 1 | 2015 | 778 | 0.100 |
Why?
|
Antigens, Bacterial | 1 | 2017 | 1155 | 0.100 |
Why?
|
Vulnerable Populations | 1 | 2017 | 703 | 0.100 |
Why?
|
Skin Care | 1 | 2012 | 57 | 0.100 |
Why?
|
Perinatal Care | 1 | 2014 | 243 | 0.100 |
Why?
|
Soot | 2 | 2024 | 221 | 0.100 |
Why?
|
Self Report | 2 | 2022 | 3724 | 0.100 |
Why?
|
Cattle | 3 | 2024 | 3848 | 0.100 |
Why?
|
Faculty | 1 | 2015 | 383 | 0.100 |
Why?
|
Influenza, Human | 1 | 2022 | 1521 | 0.090 |
Why?
|
Cocos | 1 | 2010 | 9 | 0.090 |
Why?
|
Emergency Service, Hospital | 6 | 2023 | 7874 | 0.090 |
Why?
|
Tacrolimus | 1 | 2015 | 733 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2018 | 1403 | 0.090 |
Why?
|
Anxiety | 2 | 2022 | 4572 | 0.090 |
Why?
|
Drug Industry | 1 | 2017 | 788 | 0.090 |
Why?
|
Likelihood Functions | 1 | 2013 | 992 | 0.090 |
Why?
|
Dermatophagoides farinae | 1 | 2010 | 19 | 0.090 |
Why?
|
Dietary Proteins | 3 | 2021 | 952 | 0.090 |
Why?
|
New England | 1 | 2013 | 1053 | 0.090 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 3204 | 0.090 |
Why?
|
Metabolomics | 1 | 2019 | 1657 | 0.090 |
Why?
|
Anemia, Sickle Cell | 1 | 2018 | 1064 | 0.090 |
Why?
|
Th17 Cells | 1 | 2016 | 794 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2017 | 1613 | 0.080 |
Why?
|
Mitosporic Fungi | 1 | 2009 | 17 | 0.080 |
Why?
|
Secondary Prevention | 1 | 2015 | 1474 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2019 | 10766 | 0.080 |
Why?
|
CpG Islands | 1 | 2014 | 1229 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2024 | 3204 | 0.080 |
Why?
|
Patient Selection | 1 | 2021 | 4244 | 0.080 |
Why?
|
Ecosystem | 1 | 2013 | 490 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2012 | 15262 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1197 | 0.080 |
Why?
|
Telemedicine | 2 | 2023 | 3051 | 0.080 |
Why?
|
Income | 1 | 2017 | 1876 | 0.080 |
Why?
|
Rats | 2 | 2017 | 23742 | 0.080 |
Why?
|
Follow-Up Studies | 4 | 2016 | 39117 | 0.080 |
Why?
|
RNA Viruses | 1 | 2009 | 111 | 0.070 |
Why?
|
Pregnancy | 3 | 2022 | 29862 | 0.070 |
Why?
|
Mental Health | 1 | 2022 | 3249 | 0.070 |
Why?
|
Tobacco Smoke Pollution | 1 | 2014 | 818 | 0.070 |
Why?
|
Premature Birth | 1 | 2020 | 1782 | 0.070 |
Why?
|
Humidity | 2 | 2021 | 205 | 0.070 |
Why?
|
Ambulatory Care | 1 | 2019 | 2775 | 0.070 |
Why?
|
Interleukin-13 | 2 | 2023 | 390 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1377 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20093 | 0.070 |
Why?
|
Administration, Oral | 3 | 2024 | 4016 | 0.070 |
Why?
|
Receptors, Cell Surface | 1 | 2016 | 2821 | 0.070 |
Why?
|
Prosthesis Failure | 2 | 2006 | 1204 | 0.070 |
Why?
|
Adrenal Cortex Function Tests | 1 | 2006 | 12 | 0.070 |
Why?
|
Environmental Pollution | 1 | 2008 | 123 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2273 | 0.070 |
Why?
|
Overweight | 1 | 2017 | 2413 | 0.070 |
Why?
|
ROC Curve | 2 | 2012 | 3580 | 0.070 |
Why?
|
Respiration Disorders | 1 | 2009 | 367 | 0.070 |
Why?
|
Disease Models, Animal | 4 | 2024 | 18247 | 0.070 |
Why?
|
Rhinitis, Allergic, Perennial | 2 | 2013 | 59 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 5789 | 0.070 |
Why?
|
Cytokines | 2 | 2023 | 7392 | 0.070 |
Why?
|
Biomedical Research | 2 | 2018 | 3429 | 0.060 |
Why?
|
Hot Temperature | 1 | 2012 | 1440 | 0.060 |
Why?
|
Analysis of Variance | 3 | 2020 | 6231 | 0.060 |
Why?
|
Exercise Test | 1 | 2013 | 2129 | 0.060 |
Why?
|
Dehydroepiandrosterone Sulfate | 1 | 2006 | 241 | 0.060 |
Why?
|
Quantitative Trait Loci | 1 | 2014 | 2116 | 0.060 |
Why?
|
Nutrition Surveys | 2 | 2023 | 1728 | 0.060 |
Why?
|
Polysorbates | 1 | 2005 | 43 | 0.060 |
Why?
|
Fatty Acids, Essential | 1 | 2005 | 97 | 0.060 |
Why?
|
Carbon Monoxide | 2 | 2019 | 546 | 0.060 |
Why?
|
Multivariate Analysis | 3 | 2018 | 12058 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2507 | 0.060 |
Why?
|
Inpatients | 1 | 2016 | 2548 | 0.060 |
Why?
|
Hygiene | 1 | 2005 | 94 | 0.060 |
Why?
|
Healthcare Disparities | 1 | 2020 | 3357 | 0.060 |
Why?
|
Anti-Bacterial Agents | 3 | 2021 | 7409 | 0.060 |
Why?
|
Prognosis | 3 | 2020 | 29620 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5335 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3576 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2018 | 5291 | 0.060 |
Why?
|
Adrenal Insufficiency | 1 | 2006 | 194 | 0.060 |
Why?
|
Computer Simulation | 1 | 1998 | 6238 | 0.060 |
Why?
|
Mice, Inbred BALB C | 2 | 2024 | 6215 | 0.060 |
Why?
|
Joint Prosthesis | 1 | 2006 | 253 | 0.060 |
Why?
|
Cost of Illness | 2 | 2024 | 1936 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2880 | 0.060 |
Why?
|
Survival Analysis | 1 | 2016 | 10089 | 0.060 |
Why?
|
Critical Care | 1 | 2016 | 2697 | 0.060 |
Why?
|
Specific Gravity | 1 | 2022 | 18 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8223 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2021 | 22168 | 0.050 |
Why?
|
Databases, Factual | 1 | 2018 | 7956 | 0.050 |
Why?
|
Respiratory Physiological Phenomena | 1 | 2023 | 189 | 0.050 |
Why?
|
Pituitary-Adrenal System | 2 | 2021 | 551 | 0.050 |
Why?
|
Receptors, Interleukin-4 | 1 | 2022 | 64 | 0.050 |
Why?
|
Puerto Rico | 1 | 2023 | 376 | 0.050 |
Why?
|
Fat Emulsions, Intravenous | 1 | 2005 | 314 | 0.050 |
Why?
|
Sulfonamides | 2 | 2024 | 1975 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3082 | 0.050 |
Why?
|
Qualitative Research | 2 | 2024 | 3023 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3202 | 0.050 |
Why?
|
Metered Dose Inhalers | 1 | 2022 | 25 | 0.050 |
Why?
|
Seed Storage Proteins | 1 | 2021 | 15 | 0.050 |
Why?
|
Buprenorphine | 1 | 2010 | 656 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4591 | 0.050 |
Why?
|
Fish Oils | 1 | 2005 | 483 | 0.050 |
Why?
|
Hypothalamo-Hypophyseal System | 2 | 2021 | 700 | 0.050 |
Why?
|
2S Albumins, Plant | 1 | 2021 | 37 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 286 | 0.050 |
Why?
|
Administration, Intranasal | 1 | 2003 | 477 | 0.050 |
Why?
|
Syndrome | 2 | 2020 | 3268 | 0.050 |
Why?
|
Biological Therapy | 1 | 2023 | 141 | 0.050 |
Why?
|
Histamine | 1 | 2023 | 498 | 0.050 |
Why?
|
Africa | 1 | 2023 | 710 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2642 | 0.050 |
Why?
|
Drug Hypersensitivity | 1 | 2010 | 917 | 0.050 |
Why?
|
Purines | 1 | 2024 | 605 | 0.050 |
Why?
|
Health Personnel | 3 | 2023 | 3335 | 0.050 |
Why?
|
Infusions, Parenteral | 1 | 2021 | 398 | 0.050 |
Why?
|
Oxadiazoles | 1 | 2000 | 94 | 0.050 |
Why?
|
Evidence-Based Medicine | 3 | 2022 | 3687 | 0.040 |
Why?
|
Budesonide | 1 | 2021 | 157 | 0.040 |
Why?
|
Phenylcarbamates | 1 | 2000 | 38 | 0.040 |
Why?
|
Diet | 1 | 2018 | 8074 | 0.040 |
Why?
|
Carnobacteriaceae | 1 | 2019 | 10 | 0.040 |
Why?
|
Peptide Library | 1 | 2021 | 347 | 0.040 |
Why?
|
Aged | 9 | 2024 | 169235 | 0.040 |
Why?
|
Delphi Technique | 1 | 2024 | 846 | 0.040 |
Why?
|
Moraxella | 1 | 2019 | 25 | 0.040 |
Why?
|
Androstadienes | 1 | 2021 | 348 | 0.040 |
Why?
|
Child Welfare | 1 | 2004 | 519 | 0.040 |
Why?
|
Finland | 1 | 2021 | 607 | 0.040 |
Why?
|
Radioallergosorbent Test | 1 | 1999 | 19 | 0.040 |
Why?
|
Intradermal Tests | 1 | 1999 | 42 | 0.040 |
Why?
|
Medical Records | 1 | 2005 | 1407 | 0.040 |
Why?
|
Skin | 2 | 2024 | 4481 | 0.040 |
Why?
|
Staphylococcus | 1 | 2019 | 154 | 0.040 |
Why?
|
Streptococcus | 1 | 2019 | 198 | 0.040 |
Why?
|
Time Factors | 2 | 2020 | 39975 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1755 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 629 | 0.040 |
Why?
|
Theophylline | 1 | 2019 | 131 | 0.040 |
Why?
|
Sulfur | 1 | 2019 | 162 | 0.040 |
Why?
|
Decontamination | 1 | 2019 | 72 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4852 | 0.040 |
Why?
|
Biomass | 1 | 2019 | 137 | 0.040 |
Why?
|
Antibody Formation | 1 | 2023 | 1398 | 0.040 |
Why?
|
Prosthesis Design | 1 | 2006 | 2115 | 0.040 |
Why?
|
Geography | 1 | 2021 | 656 | 0.040 |
Why?
|
Respiratory System | 1 | 2002 | 563 | 0.040 |
Why?
|
Smoking | 1 | 2015 | 9052 | 0.040 |
Why?
|
Consensus | 2 | 2023 | 3122 | 0.040 |
Why?
|
Carbon | 1 | 2022 | 665 | 0.040 |
Why?
|
Lubrication | 1 | 1998 | 21 | 0.040 |
Why?
|
Ventilation | 1 | 2019 | 128 | 0.040 |
Why?
|
Severe Combined Immunodeficiency | 1 | 2000 | 226 | 0.040 |
Why?
|
Aluminum Oxide | 1 | 1998 | 41 | 0.040 |
Why?
|
Ornithine | 1 | 2018 | 79 | 0.040 |
Why?
|
Age of Onset | 1 | 2005 | 3304 | 0.040 |
Why?
|
Prednisolone | 1 | 2019 | 326 | 0.040 |
Why?
|
Convalescence | 1 | 2018 | 105 | 0.040 |
Why?
|
Chronic Disease | 3 | 2022 | 9320 | 0.040 |
Why?
|
Cobalt | 1 | 1998 | 154 | 0.040 |
Why?
|
Steroids | 1 | 2003 | 929 | 0.040 |
Why?
|
Consensus Development Conferences, NIH as Topic | 1 | 2017 | 28 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2021 | 857 | 0.040 |
Why?
|
Guideline Adherence | 1 | 2008 | 2220 | 0.040 |
Why?
|
Advisory Committees | 1 | 2021 | 786 | 0.040 |
Why?
|
Chromium | 1 | 1998 | 132 | 0.040 |
Why?
|
Polysomnography | 1 | 2024 | 1847 | 0.040 |
Why?
|
Acoustics | 1 | 1998 | 242 | 0.040 |
Why?
|
Creatinine | 1 | 2022 | 1899 | 0.030 |
Why?
|
Genotype | 2 | 2022 | 13009 | 0.030 |
Why?
|
Trachea | 1 | 2023 | 1089 | 0.030 |
Why?
|
Fund Raising | 1 | 2017 | 49 | 0.030 |
Why?
|
Mast Cells | 1 | 2024 | 1391 | 0.030 |
Why?
|
Nasal Cavity | 1 | 1998 | 304 | 0.030 |
Why?
|
GRB2 Adaptor Protein | 1 | 2016 | 101 | 0.030 |
Why?
|
Acute Disease | 2 | 2018 | 7238 | 0.030 |
Why?
|
Life Change Events | 1 | 2022 | 952 | 0.030 |
Why?
|
Vomiting | 1 | 2000 | 652 | 0.030 |
Why?
|
Aged, 80 and over | 4 | 2022 | 58956 | 0.030 |
Why?
|
Aftercare | 1 | 2022 | 914 | 0.030 |
Why?
|
Nurse's Role | 1 | 2017 | 188 | 0.030 |
Why?
|
Manometry | 1 | 1998 | 454 | 0.030 |
Why?
|
Appointments and Schedules | 1 | 2020 | 443 | 0.030 |
Why?
|
Absenteeism | 1 | 2017 | 247 | 0.030 |
Why?
|
Growth | 1 | 2018 | 365 | 0.030 |
Why?
|
Nigeria | 1 | 2019 | 770 | 0.030 |
Why?
|
Incidence | 2 | 2016 | 21341 | 0.030 |
Why?
|
Violence | 1 | 2022 | 937 | 0.030 |
Why?
|
High-Throughput Screening Assays | 1 | 2021 | 934 | 0.030 |
Why?
|
Ambulatory Care Facilities | 1 | 2022 | 934 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1998 | 1626 | 0.030 |
Why?
|
Immunophenotyping | 1 | 2020 | 1870 | 0.030 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2016 | 152 | 0.030 |
Why?
|
Gestational Age | 1 | 2004 | 3576 | 0.030 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1843 | 0.030 |
Why?
|
Reoperation | 1 | 2006 | 4303 | 0.030 |
Why?
|
Receptors, Interleukin-6 | 1 | 2016 | 225 | 0.030 |
Why?
|
Surface Properties | 1 | 1998 | 1160 | 0.030 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2018 | 370 | 0.030 |
Why?
|
Puberty | 1 | 2018 | 501 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1551 | 0.030 |
Why?
|
Cough | 1 | 2018 | 594 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2019 | 1146 | 0.030 |
Why?
|
Environmental Health | 1 | 2017 | 289 | 0.030 |
Why?
|
Temperature | 1 | 2021 | 2228 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2019 | 664 | 0.030 |
Why?
|
Mouth Mucosa | 1 | 2017 | 431 | 0.030 |
Why?
|
Breast Feeding | 1 | 2023 | 1358 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2016 | 878 | 0.030 |
Why?
|
Occupational Exposure | 1 | 2024 | 1813 | 0.030 |
Why?
|
Proteins | 1 | 2009 | 6032 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2007 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2597 | 0.030 |
Why?
|
Risk Assessment | 2 | 2018 | 23990 | 0.030 |
Why?
|
Analgesics, Opioid | 1 | 2010 | 3804 | 0.030 |
Why?
|
Outpatients | 1 | 2022 | 1597 | 0.030 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 12970 | 0.030 |
Why?
|
Recurrence | 2 | 2016 | 8469 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 2048 | 0.030 |
Why?
|
Patient Care Management | 1 | 2016 | 302 | 0.030 |
Why?
|
Immunoblotting | 1 | 2016 | 1647 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 8000 | 0.030 |
Why?
|
Social Support | 1 | 2023 | 2172 | 0.030 |
Why?
|
Logistic Models | 2 | 2004 | 13255 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 1998 | 1674 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2019 | 1989 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2024 | 2746 | 0.030 |
Why?
|
Metabolome | 1 | 2019 | 987 | 0.030 |
Why?
|
T-Lymphocyte Subsets | 1 | 2020 | 1806 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2019 | 2706 | 0.020 |
Why?
|
Pyrimidines | 1 | 2024 | 3027 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 871 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3423 | 0.020 |
Why?
|
Indoles | 1 | 2000 | 1832 | 0.020 |
Why?
|
Sex Distribution | 1 | 2017 | 2281 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3823 | 0.020 |
Why?
|
Water | 1 | 1998 | 1410 | 0.020 |
Why?
|
Research | 1 | 2020 | 1977 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2024 | 9535 | 0.020 |
Why?
|
Pediatrics | 1 | 2006 | 3595 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3418 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17912 | 0.020 |
Why?
|
Administration, Sublingual | 1 | 2010 | 58 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2016 | 911 | 0.020 |
Why?
|
Air Conditioning | 1 | 2009 | 54 | 0.020 |
Why?
|
Health Education | 1 | 2016 | 1052 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2019 | 1588 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2723 | 0.020 |
Why?
|
Patient Discharge | 1 | 2022 | 3441 | 0.020 |
Why?
|
Expert Testimony | 1 | 2012 | 363 | 0.020 |
Why?
|
Program Evaluation | 1 | 2017 | 2494 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4575 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3639 | 0.020 |
Why?
|
Interferon-gamma | 1 | 2017 | 3159 | 0.020 |
Why?
|
Drug Resistance, Bacterial | 1 | 2015 | 1048 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2021 | 4764 | 0.020 |
Why?
|
Linear Models | 1 | 2018 | 5869 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7584 | 0.020 |
Why?
|
Odds Ratio | 1 | 2019 | 9645 | 0.020 |
Why?
|
Cosyntropin | 1 | 2006 | 34 | 0.020 |
Why?
|
Insurance, Health | 1 | 2019 | 2497 | 0.020 |
Why?
|
Exercise | 1 | 2023 | 5884 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5868 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6479 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6581 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22163 | 0.020 |
Why?
|
Proteomics | 1 | 2018 | 3845 | 0.020 |
Why?
|
Primary Health Care | 1 | 2021 | 4686 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2021 | 7856 | 0.010 |
Why?
|
Medicaid | 1 | 2017 | 2818 | 0.010 |
Why?
|
Neutrophils | 1 | 2017 | 3766 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5840 | 0.010 |
Why?
|
Pain | 1 | 2016 | 5071 | 0.010 |
Why?
|
Parenteral Nutrition | 1 | 2005 | 659 | 0.010 |
Why?
|
Hypertension | 1 | 2020 | 8542 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2016 | 9418 | 0.010 |
Why?
|
Oxazoles | 1 | 2000 | 199 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2016 | 11526 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2006 | 1815 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2021 | 20556 | 0.010 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2005 | 1116 | 0.010 |
Why?
|
Body Height | 1 | 2004 | 1570 | 0.010 |
Why?
|
Energy Intake | 1 | 2005 | 2134 | 0.010 |
Why?
|
Bone Marrow Transplantation | 1 | 2005 | 2695 | 0.010 |
Why?
|
Patient Compliance | 1 | 2008 | 2690 | 0.010 |
Why?
|
Birth Weight | 1 | 2004 | 2100 | 0.010 |
Why?
|
Infant, Premature | 1 | 2004 | 2104 | 0.010 |
Why?
|
Feces | 1 | 2000 | 1497 | 0.010 |
Why?
|
RNA, Viral | 1 | 2000 | 2846 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2000 | 6086 | 0.010 |
Why?
|